Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,223,251 papers from all fields of science
Search
Sign In
Create Free Account
acetylacetoin reductase (NADH)
Known as:
AACR II
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Long Noncoding RNA and Cancer: A New Paradigm.
A. Bhan
,
Milad Soleimani
,
S. Mandal
Cancer Research
2017
Corpus ID: 1905909
In addition to mutations or aberrant expression in the protein-coding genes, mutations and misregulation of noncoding RNAs, in…
Expand
Review
2017
Review
2017
Breast Cancer Immunotherapy: Facts and Hopes
L. Emens
Clinical Cancer Research
2017
Corpus ID: 20996173
Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of…
Expand
Highly Cited
2016
Highly Cited
2016
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
P. Ballard
,
J. Yates
,
+14 authors
D. Cross
Clinical Cancer Research
2016
Corpus ID: 19304422
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC) harboring tumors with EGFR-tyrosine kinase…
Expand
Highly Cited
2016
Highly Cited
2016
Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype.
Ling Li
,
Chao Li
,
+8 authors
G. Zhu
Cancer Research
2016
Corpus ID: 5081440
Hypoxia is a common feature of solid tumors and is associated with aggressiveness and poor patient outcomes. Exosomes, initially…
Expand
Review
2016
Review
2016
DNA Methylation in Cancer and Aging.
M. Klutstein
,
D. Nejman
,
Razi Greenfield
,
H. Cedar
Cancer Research
2016
Corpus ID: 8898262
DNA methylation is known to be abnormal in all forms of cancer, but it is not really understood how this occurs and what is its…
Expand
Highly Cited
2016
Highly Cited
2016
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
M. T. Herrera-Abreu
,
M. Palafox
,
+16 authors
V. Serra
Cancer Research
2016
Corpus ID: 207669712
Small-molecule inhibitors of the CDK4/6 cell-cycle kinases have shown clinical efficacy in estrogen receptor (ER)-positive…
Expand
Highly Cited
2016
Highly Cited
2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
A. Martens
,
K. Wistuba-Hamprecht
,
+21 authors
B. Weide
Clinical Cancer Research
2016
Corpus ID: 12384896
Purpose: To identify baseline peripheral blood biomarkers associated with clinical outcome following ipilimumab treatment in…
Expand
Highly Cited
2016
Highly Cited
2016
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
E. Stelloo
,
R. Nout
,
+9 authors
V. Smit
Clinical Cancer Research
2016
Corpus ID: 179061
Purpose: Recommendations for adjuvant treatment for women with early-stage endometrial carcinoma are based on clinicopathologic…
Expand
Highly Cited
2016
Highly Cited
2016
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Y. Ogitani
,
T. Aida
,
+13 authors
T. Agatsuma
Clinical Cancer Research
2016
Corpus ID: 12462981
Purpose: An anti-HER2 antibody–drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor…
Expand
Review
2015
Review
2015
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.
A. Hata
,
J. Engelman
,
A. Faber
Cancer Discovery
2015
Corpus ID: 2963192
UNLABELLED The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2 family proteins comprise…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE